Conservative Kidney Management: When, Why, and For Whom?

被引:1
|
作者
Li, Kelly Chenlei [1 ,2 ]
Brown, Mark Ashley [1 ]
机构
[1] Univ New South Wales, St George Hosp, Renal Dept, Sydney, Australia
[2] 50 Montgomery St,Suite 1, Kogarah, NSW 2217, Australia
关键词
Shared decision making; kidney failure; end stage kidney disease; conservative kidney management; kidney supportive care; palliative care; STAGE RENAL-DISEASE; OF-LIFE; PALLIATIVE CARE; COMPARATIVE SURVIVAL; STARTING DIALYSIS; ELDERLY-PATIENTS; DECISION-MAKING; OLDER PATIENTS; CKD; PATIENT;
D O I
10.1016/j.semnephrol.2023.151395
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Deciding between dialysis and conservative kidney management (CKM) in an elderly or seriously ill per-son with kidney failure is complex and requires shared decision making. Patients and families look to their nephrolo-gist to provide an individualized recommendation that aligns with patient-centered goals. For a balanced and considered decision to be made, dialysis should not be the default and nephrologists need to be familiar with rele-vant prognostic information including survival, symptom burden, functional trajectory, and quality of life with dialysis and with CKM. CKM is a holistic, proactive, and multidisciplinary treatment for kidney failure. For some elderly comorbid patients, CKM improves symptom burden and aligns with quality-of-life goals, with modest or no loss of longevity. CKM can be provided by a nephrologist alone but ideally is managed through partnership with a dedi-cated supportive or palliative care service embedded within the nephrology practice. Treatment decisions are best discussed early in the disease trajectory and occur over many consultations, and nephrologists should be upskilled in communication to better support patients and families in these important conversations. Nephrologists should remain actively involved in their patients' care through to end-of-life care. Semin Nephrol 43:151395 & COPY; 2023 Elsevier Inc. All rights reserved.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Size matters but when, why and for whom?
    Blackwell, Anna K. M.
    Lee, Ilse
    Scollo, Michelle
    Wakefield, Melanie
    Munafo, Marcus R.
    Marteau, Theresa M.
    ADDICTION, 2020, 115 (05) : 815 - 816
  • [2] Dyslipidemia testing: Why, for whom and when
    Galema-Boers, J. M. H.
    van Lennep, J. E. Roeters
    MATURITAS, 2015, 81 (04) : 442 - 445
  • [3] Making sense of refractive surgery in 2001: Why, when, for whom, and by whom?
    Mannis, MJ
    Segal, WA
    Darlington, JK
    MAYO CLINIC PROCEEDINGS, 2001, 76 (08) : 823 - 829
  • [4] ARTHROGRAPHY FOR RHEUMATIC DISEASE - WHEN, WHY, AND FOR WHOM
    GOLDMAN, AB
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1991, 17 (03) : 505 - 542
  • [5] Advanced Lipid Testing: When, Why, and In Whom?
    Watson, Karol E.
    Stocker, Eric H.
    Jacoby, Douglas S.
    McCullough, Peter A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2014, 15 (04) : 311 - 319
  • [6] Tranexamic acid for childbirth: why, when, and for whom
    Sentilhes, Loic
    Madar, Hugo
    Mattuizzi, Aurelien
    Froeliger, Alizee
    Merlot, Benjamin
    Elleboode, Benoit
    Deneux-Tharaux, Catherine
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (09) : 753 - 761
  • [7] Antibiotic prophylaxis in COPD: Why, when, and for whom?
    Miravitlles, Marc
    Anzueto, Antonio
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 32 : 119 - 123
  • [8] Laparoscopic myomectomy today - Why, when and for whom?
    Nezhat, F
    Seidman, DS
    Nezhat, C
    Nezhat, CH
    HUMAN REPRODUCTION, 1996, 11 (05) : 933 - 934
  • [9] Conservative Kidney Management in Kidney
    Murakami, Naoka
    Reich, Amanda J.
    Pavlakis, Martha
    Lakin, Joshua R.
    SEMINARS IN NEPHROLOGY, 2023, 43 (01)
  • [10] Giving an Account: When, Where, for Whom, and Why?
    Butler, Judith
    DIFFERENCES-A JOURNAL OF FEMINIST CULTURAL STUDIES, 2024, 35 (03) : 224 - 236